Logo image of AKYA

AKOYA BIOSCIENCES INC (AKYA) Stock Fundamental Analysis

NASDAQ:AKYA - Nasdaq - US00974H1041 - Common Stock - Currency: USD

2.69  +0.07 (+2.67%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AKYA. AKYA was compared to 57 industry peers in the Life Sciences Tools & Services industry. AKYA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AKYA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKYA has reported negative net income.
In the past year AKYA has reported a negative cash flow from operations.
In the past 5 years AKYA always reported negative net income.
AKYA had a negative operating cash flow in each of the past 5 years.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

AKYA has a worse Return On Assets (-44.60%) than 82.46% of its industry peers.
AKYA has a Return On Equity of -425.20%. This is amonst the worse of the industry: AKYA underperforms 92.98% of its industry peers.
Industry RankSector Rank
ROA -44.6%
ROE -425.2%
ROIC N/A
ROA(3y)-32.83%
ROA(5y)-29.39%
ROE(3y)-91.62%
ROE(5y)-89.72%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

AKYA has a Gross Margin of 57.72%. This is in the better half of the industry: AKYA outperforms 75.44% of its industry peers.
In the last couple of years the Gross Margin of AKYA has declined.
The Profit Margin and Operating Margin are not available for AKYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.54%
GM growth 5YN/A
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKYA has more shares outstanding
Compared to 1 year ago, AKYA has a worse debt to assets ratio.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

AKYA has an Altman-Z score of -2.32. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.32, AKYA is doing worse than 82.46% of the companies in the same industry.
A Debt/Equity ratio of 5.62 is on the high side and indicates that AKYA has dependencies on debt financing.
AKYA's Debt to Equity ratio of 5.62 is on the low side compared to the rest of the industry. AKYA is outperformed by 92.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.62
Debt/FCF N/A
Altman-Z -2.32
ROIC/WACCN/A
WACC11.36%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

AKYA has a Current Ratio of 2.75. This indicates that AKYA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AKYA (2.75) is comparable to the rest of the industry.
A Quick Ratio of 1.85 indicates that AKYA should not have too much problems paying its short term obligations.
AKYA has a Quick ratio (1.85) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 1.85
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

4

3. Growth

3.1 Past

AKYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.99%, which is quite impressive.
AKYA shows a decrease in Revenue. In the last year, the revenue decreased by -4.99%.
The Revenue has been growing by 31.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)30.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
Revenue 1Y (TTM)-4.99%
Revenue growth 3Y31.56%
Revenue growth 5YN/A
Sales Q2Q%-25.12%

3.2 Future

The Earnings Per Share is expected to grow by 11.66% on average over the next years. This is quite good.
Based on estimates for the next years, AKYA will show a small growth in Revenue. The Revenue will grow by 4.60% on average per year.
EPS Next Y21.9%
EPS Next 2Y24.77%
EPS Next 3Y18.95%
EPS Next 5Y11.66%
Revenue Next Year-14.84%
Revenue Next 2Y-2.44%
Revenue Next 3Y3.14%
Revenue Next 5Y4.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as AKYA's earnings are expected to grow with 18.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.77%
EPS Next 3Y18.95%

More info and screens

0

5. Dividend

5.1 Amount

AKYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (2/5/2025, 9:36:10 AM)

2.69

+0.07 (+2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners31.53%
Inst Owner Change-0.36%
Ins Owners4.04%
Ins Owner Change14.21%
Market Cap133.32M
Analysts75.71
Price Target3.57 (32.71%)
Short Float %8.46%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.05%
Min EPS beat(2)-1.05%
Max EPS beat(2)1.15%
EPS beat(4)2
Avg EPS beat(4)-10.8%
Min EPS beat(4)-62.97%
Max EPS beat(4)19.69%
EPS beat(8)4
Avg EPS beat(8)-3.53%
EPS beat(12)4
Avg EPS beat(12)-9.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.51%
Min Revenue beat(2)-27.44%
Max Revenue beat(2)-3.58%
Revenue beat(4)1
Avg Revenue beat(4)-14.16%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)0.3%
Revenue beat(8)5
Avg Revenue beat(8)-6.14%
Revenue beat(12)8
Avg Revenue beat(12)-2.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-30%
EPS NQ rev (1m)-7.5%
EPS NQ rev (3m)-18.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.09%
Revenue NQ rev (1m)-6.25%
Revenue NQ rev (3m)-34.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B 9.78
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS1.75
BVpS0.28
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.6%
ROE -425.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.72%
FCFM N/A
ROA(3y)-32.83%
ROA(5y)-29.39%
ROE(3y)-91.62%
ROE(5y)-89.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.54%
GM growth 5YN/A
F-Score3
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 5.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.37%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 1.85
Altman-Z -2.32
F-Score3
WACC11.36%
ROIC/WACCN/A
Cap/Depr(3y)83.43%
Cap/Depr(5y)86.09%
Cap/Sales(3y)7.63%
Cap/Sales(5y)7.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
EPS Next Y21.9%
EPS Next 2Y24.77%
EPS Next 3Y18.95%
EPS Next 5Y11.66%
Revenue 1Y (TTM)-4.99%
Revenue growth 3Y31.56%
Revenue growth 5YN/A
Sales Q2Q%-25.12%
Revenue Next Year-14.84%
Revenue Next 2Y-2.44%
Revenue Next 3Y3.14%
Revenue Next 5Y4.6%
EBIT growth 1Y32.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.63%
EBIT Next 3Y22.01%
EBIT Next 5Y15.77%
FCF growth 1Y14.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.37%
OCF growth 3YN/A
OCF growth 5YN/A